Insilico Medicine Taiwan Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI 2024-03-13 08:00
Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD) 2023-12-05 06:00
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor 2023-09-13 20:29
Insilico Medicine Nominates Preclinical Candidate of Inhalation Solution for ISM001-055, the First Generative AI IPF Drug 2023-07-22 14:37
First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed 2023-06-27 21:00
Insilico Medicine Successfully Explores the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry 2023-05-17 18:00
Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target 2023-01-10 05:00
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion 2022-11-08 22:00
Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine 2022-07-08 04:00
Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory 2022-06-06 21:00
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment 2022-05-25 05:00
Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers 2022-05-06 05:00
1